深圳新星(603978.SH):擬1億元參與設立合夥企業
格隆匯5月7日丨深圳新星(603978.SH)公佈,公司擬與洛陽國宏資本創業投資有限公司、洛陽市產業發展基金合夥企業(有限合夥)共同設立合夥企業洛陽工控新星創業投資合夥企業(有限合夥)(暫定名,以工商登記爲準),合夥企業認繳出資總額爲人民幣50,000萬元,其中公司作爲有限合夥人,擬認繳出資人民幣10,000萬元,佔合夥企業認繳出資總額的20%,其中首期投資金額爲人民幣4,200萬元。合夥企業成立的目的是以專項基金定向投資於公司全資子公司新星輕合金材料(洛陽)有限公司,爲其日常經營發展提供資金支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.